Skip to main content
Clinical Trials/NCT02042261
NCT02042261
Completed
Not Applicable

The Role of Therapeutic Drug Monitoring in Tuberculosis - a Pilot Study

Thomas Schon2 sites in 1 country38 target enrollmentJanuary 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Active Tuberculosis
Sponsor
Thomas Schon
Enrollment
38
Locations
2
Primary Endpoint
Rifampicin concentration in relationship to MIC over 10
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

Drug resistant TB is increasing and in order to enchance the efficacy of the current drugs, individualized therapy using plasma drug concentrations and minimal inhibitory concentration (MIC) determination may be of importance. This concept is defined as therapeutic drug monitoring (TDM).

In this pilot study our hypothesis is that the ratio between MIC and drug concentration data is correlated to the bacterial load measured as time to positive liquid culture (TTP).

In two sites in Sweden (Linköping and Karolinska Hospital Solna, Stockholm), 25 patients with pulmonary tuberculosis will be recruited. MIC-determination of Mycobacterium tuberculosis will be performed in BACTEC 960 MGIT and drug concentration will be determined at 2, 4 and 12 weeks after treatment initiation using LC-MS/MS methodology. Sputum cultures will be obtained at 0, 2 days, 7 days, 2 weeks, 4 weeks and 8 weeks and TTP will be measured in duplicate samples. Clinical follow up according to WHO criteria will be performed 1 year after completion of treatment.

Registry
clinicaltrials.gov
Start Date
January 2012
End Date
March 2016
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Thomas Schon
Responsible Party
Sponsor Investigator
Principal Investigator

Thomas Schon

MD PhD

Linkoeping University

Eligibility Criteria

Inclusion Criteria

  • Age\>18 years, culture verified tuberculosis

Exclusion Criteria

  • Other infectious diseases other than HIV or tuberculosis

Outcomes

Primary Outcomes

Rifampicin concentration in relationship to MIC over 10

Time Frame: 2 weeks

Secondary Outcomes

  • Cure rate on Clinical follow up (according to WHO criteria) in relation to rifampicin concentration at week 2(1 year)
  • Sputum Culture conversion in relation to rifampicin, isoniazid and pyrazinamid concentration week 2(2 and 8 weeks)
  • TB-score in relation to rifampicin, isoniazid and pyrazinamid concentration week 2(8 weeks)
  • Time to positive Culture (TTP) in relation to isoniazid, ethambutol and pyrazinamid serum concentration and minimal inhibitory concentration (MIC)(2 and 8 weeks)
  • Time to positive Culture (TTP) in relation to rifampicin serum concentration and minimal inhibitory concentration (MIC)(2weeks)

Study Sites (2)

Loading locations...

Similar Trials